BBP vs. SBIO

In the year-to-date period, BBP achieves a -7.64% return, which is significantly higher than SBIO's -14.22% return. Over the past 10 years, BBP has outperformed SBIO with an annualized return of 5.96%, while SBIO has yielded a comparatively lower -0.33% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

BBP has a 0.79% expense ratio, which is higher than SBIO's 0.50% expense ratio.

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BBP Sharpe Ratio is 0.02, which is higher than the SBIO Sharpe Ratio of -0.38. The chart below compares the historical Sharpe Ratios of BBP and SBIO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BBP has not paid dividends to shareholders, while SBIO's dividend yield for the trailing twelve months is around 4.14%.

The maximum BBP drawdown since its inception was -44.32%, smaller than the maximum SBIO drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for BBP and SBIO. For additional features, visit the drawdowns tool.

The current volatility for Virtus LifeSci Biotech Products ETF (BBP) is 9.82%, while ALPS Medical Breakthroughs ETF (SBIO) has a volatility of 12.44%. This indicates that BBP experiences smaller price fluctuations and is considered to be less risky than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.